aml中的分子学监测.pptVIP

All mutations occurred as an insertion of four nucleotides at position 960, except for type VII, which had an insertion at position 964. Method: The PCR products were purified and directly cloned into pGEM-T or pGEM-T-EASYvector. The plasmids were sequenced and the wild-type (WT) and mutant clones were used for standard curves in subsequent real-time PCR. The seven mutants were serially diluted from 106 to 10 copies per reaction and found as low as 10 copies of all mutants could be reliably detected. We used BM genomic DNA without NPM1 mutations to serially dilute the genomic DNA obtained from NPM1-mutated patients at diagnosis, and found that the sensitivity of our method could reach 105, * * * Figure 5. Outcome by MRD2 response. (A) Cumulative incidence of relapse: At 36 months, CIR was estimated at 22% [95% CI, 16-32] in patients who achieved a 3-log MRD2 reduction versus 54% [95% CI, 39-69] in those who did not (SHR= 0.27 [95% CI, 0.15-0.49]; P0.001 by cause-specific hazard Cox model). Overall survival from CR: At 36 months, OS from CR was estimated at 90% [95% CI, 83-94] in patients who achieved a 3-log MRD2 reduction versus 71% [95% CI, 51-85] in those who did not (HR= 0.43 [95% CI, 0.17-1.08];, P=0.066 by the log-rank test). * Assessment of minimal residual disease using the European Leukemia-Net WT1 assay following induction chemotherapy predicts risk of relapse in acute myeloid leukemia (AML). Normalized WT1 transcript level was compared between paired pretreatment and postinduction samples derived from 91 AML patients with a pretreatment WT1 expression level ( 2 104 WT1 copies/104 ABL copies) sufficient to allow discrimination of at least a 2-log reduction in transcripts following induction. * Actuarial survival and cumulative incidence of leukemia relapse in patients with acute leukemia undergoing an allogeneic stem cell transplantation. The patients are divided into 3 groups: MRDDLI, n 17 (patients with positive minimal residual disease, receiving dono